For the thousands of Indian families living with transfusion-dependent thalassemia, 2026 brings a new horizon of hope: the arrival of Affordable Genomic Medicine. While gene therapies like CRISPR-based treatments have been available globally, their multi-million dollar price tags remained out of reach for the average Indian patient. This year, however, domestic biotech firms and research...